Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

Abstract Background Infants with congenital heart disease (CHD) have an increased risk of morbidity and mortality during a respiratory syncytial virus (RSV) infection. The aim of this study was to estimate the cost-effectiveness of palivizumab as RSV-prophylaxis among infants with CHD, including the...

Full description

Bibliographic Details
Main Authors: Eva Fernlund, Martin Eriksson, Jonas Söderholm, Jan Sunnegårdh, Estelle Naumburg
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Journal of Congenital Cardiology
Subjects:
Congenital heart defect
Cost-effectiveness analyses
Palivizumab
Prophylaxis
RSV-infection
Online Access:http://link.springer.com/article/10.1186/s40949-020-00036-w

Internet

http://link.springer.com/article/10.1186/s40949-020-00036-w

Similar Items